<DOC>
	<DOCNO>NCT00915603</DOCNO>
	<brief_summary>This randomize , double blind , placebo control trial evaluate impact add everolimus combination weekly paclitaxel plus bevacizumab first-line treatment woman HER2-negative metastatic breast cancer . Patients randomize ( 1:1 ) receive either paclitaxel/bevacizumab/everolimus ( Treatment Arm 1 ) paclitaxel/ bevacizumab/placebo ( Treatment Arm 2 ) . Patients evaluated response treatment every 8 week ; respond and/or stable patient continue treatment , re-evaluations every 8 week , tumor progression intolerable toxicity occur . Outcomes assess treatment arm separately . This trial intend compare treatment arm primarily . Any analysis exploratory conduct without adjustment multiple hypothesis testing .</brief_summary>
	<brief_title>Trial Paclitaxel/Bevacizumab +/- Everolimus Patients With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Female male patient &gt; =18 year age . 2 . Histologically confirm invasive breast cancer , locally unresectable metastatic . 3 . No prior chemotherapy MBC . Patients may receive adjuvant neoadjuvant chemotherapy ( include taxanes and/or bevacizumab ) long treat complete &gt; 12 month prior relapse . Prior hormonal therapy adjuvant metastatic setting permit . 4 . Prior hormonal therapy adjuvant metastatic setting permit . Estrogen receptor positive patient consider candidate chemotherapy . 5 . HER2negative breast cancer , define follow : FISHnegative ( FISH ratio &lt; 2.2 ) , IHC 01+ , IHC 23+ AND FISHnegative ( FISH ratio &lt; 2.2 ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 7 . Adequate hematologic function , define : 路 Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Platelet count &gt; =100,000/mm3 Hemoglobin &gt; 9 g/dL 8 . Adequate liver function , define : 路 AST ALT &lt; =2.5 x upper limit normal ( ULN ) &lt; =5 x ULN presence liver metastases Total bilirubin &lt; =1.5 x ULN 9 . Adequate renal function , define : 路 Serum creatinine &lt; =1.5 x ULN calculate creatinine clearance &gt; =40 ml/min 10. International normalize ratio ( INR ) &lt; =1.5 prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit ( WNL ) institution ( patient anticoagulation therapy ) . Patients receive anticoagulation treatment agent warfarin heparin eligible INR stable within therapeutic range prior study treatment initiation . 11 . Adequate lipid profile : total cholesterol &lt; =300 mg/dL OR &lt; =7.75 mmol/L fast triglyceride 2.5 x ULN . Note : In case one threshold exceed , patient include initiation appropriate lipid lower medication . 12 . Patients proteinuria screen demonstrate either : 路 Urine protein creatinine ( UPC ) ration &gt; 1.0 screen Urine dipstick proteinuria &gt; =2+ ( patient discover &gt; =2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; 1 g protein 24 hour eligible ) . 13 . Measurable disease RECIST criterion . 14 . Life expectancy &gt; =12 week . 15 . Ability swallow oral medication . 16 . Adequate cardiac function , define baseline leave ventricular ejection fraction ( LVEF ) value &gt; = normal per institutional guideline MUGA scan echocardiogram ( ECHO ) . 17 . Adequate recovery recent surgery . Major surgical procedure &gt; 28 day study entry Minor surgical procedure &gt; 7 day study entry ( Portacath placement except patient start treatment &lt; 7 day portacath placement . ) 18 . Patients previous history invasive cancer ( include breast cancer ) eligible definitive treatment complete 5 year prior initiate current study treatment , evidence recurrent disease . 19 . Patient must accessible treatment followup . 20 . All patient must able understand investigational nature study give write informed consent prior study entry . 1 . Patients active brain metastasis meningeal metastasis . Patients brain metastasis resect , receive brain radiation therapy &gt; 4 week prior study entry eligible , meet follow criterion : 1 ) residual symptom &lt; grade 2 , 2 ) dexamethasone requirement , 3 ) followup MRI show regression lesion treatment new lesion appear . 2 . Previous treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) antiangiogenesis agent unless : adjuvant setting , &gt; =12 month prior recurrence . 3 . Previous radiotherapy metastatic disease complete &lt; 2 week prior study treatment initiation . 4 . Patients current receive systemic cancer therapy receive previous systemic therapy within 4 week start study drug ( e.g . chemotherapy , antibody therapy , target agent ) . 5 . Women pregnant lactating . All patient reproductive potential must agree use effective contraception time study entry least 3 month last administration study drug . 6 . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg , despite optimal medical management . 7 . Concurrent use CYP3A4 inhibitor inducers 72 hour prior initiation study treatment end treatment everolimus . 8 . Cardiac disease , include : congestive heart failure ( CHF ) &gt; Class II per New York Heart Association ( NYHA ) classification ; unstable angina ( anginal symptom rest ) newonset angina ( i.e. , begin within last 3 month ) , myocardial infarction within past 6 month ; symptomatic CHF , unstable angina pectoris , cardiac ventricular arrhythmia require antiarrhythmic therapy . 9 . History stroke transient ischemic attack within 6 month prior first bevacizumab dose . 10 . Patients nonhealing wound , ulcer , longbone fracture . 11 . Patients clinical history hemoptysis hematemesis . 12 . Patients history bleed diathesis coagulopathy . 13 . Patients PEG G tube enrol trial . 14 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior begin bevacizumab . 15 . Patients impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 16 . Patients severe and/or uncontrolled medical condition condition could affect participation : severe impaired lung function define spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN . 17 . History disease , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication . 18 . History hypersensitivity Cremophor EL ( polyoxyethylated castor oil ) drug formulate Cremophor EL , paclitaxel . 19 . Patients may receive investigational anticancer treatment participate study . 20 . Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . 21 . Patients receive immunization attenuate live vaccine within one week study entry study period . 22 . Concurrent severe , uncontrolled infection intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 23 . Patients know hypersensitivity RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) excipients . 24 . Patients know HIV seropositivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Everolimus</keyword>
</DOC>